Asian Insight Provider - Actionable ideas, CrossASEAN Research

Henry Soediarko

A Long & Short Investment Ideas generator for Asian Equities with 10 years experience in a Hedge fund focused on bottom-up ideas, searching out mispriced ideas and misunderstood investment thesis. Provides on-the-ground insights in various Asian markets with a sway towards ASEAN. Experienced and survived the Asian Financial Crisis in a family business, as well as the Global Financial Crisis in financial markets where lessons learned. It's all about understanding business drivers and navigating business cycles, which has high applicability in generating investment ideas. 

Investment horizon: Mid to Long term

Asian Insight Provider - Actionable ideas

The Week that Was in ASEAN@Smartkarma - Thai Banks, BCA, and Thai Union

Sido Muncul (SIDO IJ) - A Consumer Health Gem

Sido Muncul (SIDO): Switch, Competitor and Split

Mitra Keluarga (MIKA): Margin Expansion from COVID-19

Battle Lines Drawn As BABA Builds Out First/Last-Mile Capacity; But Who Will Fund 75+ Bn CNY CapEx?

Bluebird (BIRD): Correlated with PSBB, Beneficiary of WFH to WFO Switch

CrossASEAN Research

At CrossASEAN Research we strive to produce unbiased and differentiated on the ground insights on companies across South East Asia. Our Research is produced for the most part after face to face meetings and conversations with company management to dig deep into the long term vision and strategy of the companies we cover. We seek to deliver investable and actionable themes on sectors and markets across SE Asia, often in collaboration with other Insight Providers across the region, pooling the vast experience of the analysts within the Smartkarma Ecosystem. We also offer bespoke work and tailor made trips for our clients. 

Insights across South East Asia

Equity Bottom-Up

<p>The vaccination has already started in Indonesia and although it may take 15 months to complete, it could be an early catalyst for investors to start booking profit on SIDO especially after it made 25% last year. The business will still grow as Tolak Angin remains the most affordable solution for an immune system compared to the other local and imported brands such as <a href="https://www.smartkarma.com/entities/health-and-happiness-h-h-int" target="_blank" data-smartkarma-citation="entities:20582:1" rel="noopener">Health And Happiness (H&amp;H) (1112 HK)</a> Swisse, which are especially important when the health care system is already overwhelmed. </p>
<div class="content-highlight">
<p>Despite a 25% increase in 2020, Sido is still trading at 5%, 14%, and 26% EV/EBITDA, PER, and PBR discount respectively to the peers. </p>
</div>

The vaccination has already started in Indonesia and although it may take 15 months to complete, it could be an early catalyst for investors to start booking profit on SIDO especially after it made 25% last year. The business will still grow as Tolak Angin remains the most affordable solution for an immune system compared to the other local and imported brands such as Health And Happiness (H&amp;H) (1112 HK) Swisse, which are especially important when the health care system is already overwhelmed. 

Despite a 25% increase in 2020, Sido is still trading at 5%, 14%, and 26% EV/EBITDA, PER, and PBR discount respectively to the peers. 


Sido Muncul (SIDO): Still the Most Affordable Solution in the Pandemic